Literature DB >> 32601232

Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.

Amirhossein Mafi1, Soo-Kyung Kim1, William A Goddard2.   

Abstract

Agonists to the μ-opioid G protein-coupled receptor (μOR) can alleviate pain through activation of G protein signaling, but they can also induce β-arrestin activation, leading to such side effects as respiratory depression. Biased ligands to μOR that induce G protein signaling without inducing β-arrestin signaling can alleviate pain while reducing side effects. However, the mechanism for stimulating β-arrestin signaling is not known, making it difficult to design optimum biased ligands. We use extensive molecular dynamics simulations to determine three-dimensional (3D) structures of activated β-arrestin2 stabilized by phosphorylated μOR bound to the morphine and D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) nonbiased agonists and to the TRV130 biased agonist. For nonbiased agonists, we find that the β-arrestin2 couples to the phosphorylated μOR by forming strong polar interactions with intracellular loop 2 (ICL2) and either the ICL3 or cytoplasmic region of transmembrane (TM6). Strikingly, Gi protein makes identical strong bonds with these same ICLs. Thus, the Gi protein and β-arrestin2 compete for the same binding site even though their recruitment leads to much different outcomes. On the other hand, we find that TRV130 has a greater tendency to bind the extracellular portion of TM2 and TM3, which repositions TM6 in the cytoplasmic region of μOR, hindering β-arrestin2 from making polar anchors to the ICL3 or to the cytosolic end of TM6. This dramatically reduces the affinity between μOR and β-arrestin2.

Entities:  

Keywords:  biased agonists; molecular dynamics; nonbiased agonists

Mesh:

Substances:

Year:  2020        PMID: 32601232      PMCID: PMC7368253          DOI: 10.1073/pnas.1918264117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Agonist-induced formation of opioid receptor-G protein-coupled receptor kinase (GRK)-G beta gamma complex on membrane is required for GRK2 function in vivo.

Authors:  Jiali Li; Bin Xiang; Wenjuan Su; Xiaoqing Zhang; Yalin Huang; Lan Ma
Journal:  J Biol Chem       Date:  2003-05-15       Impact factor: 5.157

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

4.  P-LINCS:  A Parallel Linear Constraint Solver for Molecular Simulation.

Authors:  Berk Hess
Journal:  J Chem Theory Comput       Date:  2008-01       Impact factor: 6.006

5.  Automatic atom type and bond type perception in molecular mechanical calculations.

Authors:  Junmei Wang; Wei Wang; Peter A Kollman; David A Case
Journal:  J Mol Graph Model       Date:  2006-02-03       Impact factor: 2.518

6.  Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies.

Authors:  Christian Doll; Jens Konietzko; Florian Pöll; Thomas Koch; Volker Höllt; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling.

Authors:  Alex R B Thomsen; Bianca Plouffe; Thomas J Cahill; Arun K Shukla; Jeffrey T Tarrasch; Annie M Dosey; Alem W Kahsai; Ryan T Strachan; Biswaranjan Pani; Jacob P Mahoney; Liyin Huang; Billy Breton; Franziska M Heydenreich; Roger K Sunahara; Georgios Skiniotis; Michel Bouvier; Robert J Lefkowitz
Journal:  Cell       Date:  2016-08-04       Impact factor: 41.582

8.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

9.  Structure of the µ-opioid receptor-Gi protein complex.

Authors:  Antoine Koehl; Hongli Hu; Shoji Maeda; Yan Zhang; Qianhui Qu; Joseph M Paggi; Naomi R Latorraca; Daniel Hilger; Roger Dawson; Hugues Matile; Gebhard F X Schertler; Sebastien Granier; William I Weis; Ron O Dror; Aashish Manglik; Georgios Skiniotis; Brian K Kobilka
Journal:  Nature       Date:  2018-06-13       Impact factor: 49.962

10.  GPCRdb in 2018: adding GPCR structure models and ligands.

Authors:  Gáspár Pándy-Szekeres; Christian Munk; Tsonko M Tsonkov; Stefan Mordalski; Kasper Harpsøe; Alexander S Hauser; Andrzej J Bojarski; David E Gloriam
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  13 in total

1.  A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the µ-opioid receptor.

Authors:  Bing Xie; Alexander Goldberg; Lei Shi
Journal:  Comput Struct Biotechnol J       Date:  2022-05-14       Impact factor: 6.155

Review 2.  Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor.

Authors:  Ferenc Zádor; Kornél Király; Nariman Essmat; Mahmoud Al-Khrasani
Journal:  Front Mol Biosci       Date:  2022-06-13

3.  GPCR Intracellular Loop Regulation of Beta-Arrestin-Mediated Endosomal Signaling Dynamics.

Authors:  Jianing Li; Jacob M Remington; Chenyi Liao; Rodney L Parsons; Severin Schneebeli; Karen M Braas; Victor May; Matthias Brewer
Journal:  J Mol Neurosci       Date:  2022-05-10       Impact factor: 2.866

4.  Functional Characterization of Sodium Channel Inhibitors at the Delta-Opioid Receptor.

Authors:  Abdulhamid O Mohamud; Manel Zeghal; Shivani Patel; Geneviève Laroche; Nuria Blgacim; Patrick M Giguère
Journal:  ACS Omega       Date:  2022-05-12

5.  Signaling-Biased and Constitutively Active Dopamine D2 Receptor Variant.

Authors:  Dayana Rodriguez-Contreras; Alec F Condon; David C Buck; Naeem Asad; Timothy M Dore; Dineke S Verbeek; Marina A J Tijssen; Ujwal Shinde; John T Williams; Kim A Neve
Journal:  ACS Chem Neurosci       Date:  2021-05-11       Impact factor: 5.780

6.  Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.

Authors:  Justyna Piekielna-Ciesielska; Roberto Artali; Ammar A H Azzam; David G Lambert; Alicja Kluczyk; Luca Gentilucci; Anna Janecka
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

7.  Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E, protects human neurons against oxidative/neuroexcitotoxic stress via β-arrestin/ERK signaling.

Authors:  Soo-Kyung Kim; Amirhossein Mafi; Daniel Saiz-Sanchez; Vinay Kumar Sharma; Xuyu Yang; Patricia Villanueva-Anguita; Lan Xiao; Asuka Inoue; William A Goddard; Y Peng Loh
Journal:  Cell Mol Life Sci       Date:  2021-12-29       Impact factor: 9.261

8.  Identification and characterization of an atypical Gαs-biased β2AR agonist that fails to evoke airway smooth muscle cell tachyphylaxis.

Authors:  Donghwa Kim; Alina Tokmakova; Lauren K Lujan; Hannah R Strzelinski; Nicholas Kim; Maliheh Najari Beidokhti; Marc A Giulianotti; Amirhossein Mafi; Jung-A A Woo; Steven S An; William A Goddard; Stephen B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-07       Impact factor: 11.205

Review 9.  Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.

Authors:  Joaquim Azevedo Neto; Anna Costanzini; Roberto De Giorgio; David G Lambert; Chiara Ruzza; Girolamo Calò
Journal:  Molecules       Date:  2020-08-25       Impact factor: 4.411

Review 10.  Biased β-Agonists Favoring Gs over β-Arrestin for Individualized Treatment of Obstructive Lung Disease.

Authors:  Alina Tokmakova; Donghwa Kim; William A Goddard; Stephen B Liggett
Journal:  J Pers Med       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.